BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $15.57.

A number of research firms recently issued reports on BCRX. Evercore ISI boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Wedbush began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in BCRX. GF Fund Management CO. LTD. bought a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $33,000. Venturi Wealth Management LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth $48,000. KBC Group NV raised its stake in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after buying an additional 4,537 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth $80,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 2.2 %

Shares of BCRX opened at $7.54 on Friday. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -12.36 and a beta of 1.85. The stock has a 50 day moving average of $8.15 and a 200-day moving average of $7.86. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The company’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period last year, the firm posted $0.28 EPS. On average, sell-side analysts predict that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.